Paulson & CO. Inc. Maintains Position in Aradigm Corporation (ARDM)

Paulson & CO. Inc. continued to hold its position in shares of Aradigm Corporation (NASDAQ:ARDM) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 192,727 shares of the company’s stock at the end of the first quarter. Paulson & CO. Inc.’s holdings in Aradigm Corporation were worth $299,000 as of its most recent filing with the SEC.

Institutional Ownership by Quarter for Aradigm Corporation (NASDAQ:ARDM)

Aradigm Corporation (NASDAQ:ARDM) traded up 1.33% during midday trading on Friday, hitting $1.52. The stock had a trading volume of 7,123 shares. The company’s market cap is $22.50 million. Aradigm Corporation has a 1-year low of $0.78 and a 1-year high of $7.19. The company’s 50 day moving average is $1.24 and its 200 day moving average is $1.72.

Aradigm Corporation (NASDAQ:ARDM) last announced its earnings results on Monday, May 15th. The company reported ($0.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.18. Aradigm Corporation had a negative net margin of 1,515.94% and a negative return on equity of 665.03%. The company had revenue of $1.69 million for the quarter. On average, equities analysts anticipate that Aradigm Corporation will post ($1.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Paulson & CO. Inc. Maintains Position in Aradigm Corporation (ARDM)” was first posted by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

Separately, Zacks Investment Research upgraded Aradigm Corporation from a “sell” rating to a “hold” rating in a research note on Monday, June 5th.

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Want to see what other hedge funds are holding ARDM? Visit to get the latest 13F filings and insider trades for Aradigm Corporation (NASDAQ:ARDM).

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.